WebCytoAgents is a biotechnology company focused on the development of innovative pharmaceutical products for the treatment of COVID-19, Influenza, and other viral infectious diseases. Use the CB Insights Platform to explore CytoAgents's full profile. WebNov 10, 2024 · September 07, 2024. CytoAgents Announces Appointment of New Chief Medical Officer. Addition of Arthur P. Bertolino Brings World Class Capabilities to Leadership Team, Positions CytoAgents for Phase 1b/2a Clinical Trials and Strategic Pharma Partnerships to Treat Cytokine Release Syndrome. Media Coverage. February 04, 2024.

About us — esi

WebMar 15, 2024 · CytoAgents, Inc. Teresa Whalen. CytoAgents is a clinical-stage biotechnology company focused on the development of innovative pharmaceutical products to treat life-threatening symptoms associated with cytokine release syndrome, an excessive immune response that causes overwhelming inflammation. CytoAgents’ team includes … WebJun 20, 2024 · CytoAgents is a biotechnology company focused on the the treatment of COVID-19, Influenza and other viral infectious diseases. Where We Are 100 S … ct 3 news

News & Events CytoAgents

WebCytoAgents is a biotechnology company focused on the development of innovative pharmaceutical products for the treatment of COVID-19, Influenza, and other viral … WebCytoAgents has raised a total of $10.2M in funding over 9 rounds. Their latest funding was raised on Aug 11, 2024 from a Venture - Series Unknown round. CytoAgents is funded … WebHow CTO1681 Works. CytoAgents’ drug candidate, CTO1681 (formerly GP1681), prevents and treats Cytokine Release Syndrome by targeting the NF-kB signaling pathway and modulating cytokine production, resulting in reduced inflammation. NF-kB plays a critical role in the body’s natural regulation, activation, and differentiation of inflammatory ... ear pain fatigue